Schedule-dependent efficacy of camptothecins in models of human cancer

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 188-201

  Houghton, Peter J ^a   Stewart, Clinton F ^a   Zamboni, William C ^a   Thompson, Joyce ^a   Luo, Xialolong ^a   Danks, Mary K ^a   Houghton, Janet A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER MODEL; CONFERENCE PAPER; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN;

EID: 0030452955     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26388.x     Document Type: Conference Paper

References (43)

1. WANG, J. C. 1985. DNA Topoisomerases. Annu. Rev. Biochem. 54: 665-697.
2. KINGSBURY, W. D., J. C. BOEHM, D. R. JAKAS, K. G. HOLDEN, S. M. HECHT, G. GALLAGHER, M. J. CARANFA, F. L. MCCABE, L. F. FAUCETTE, R. K. JOHNSON, & R. P. HERTZBERG. 1990. Synthesis of water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 34: 98-107.
3. GOTTLIEB, J. A. & J. LUCE. 1972. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep. 56: 103-105.
4. GOTTLIEB, J. A., A. M. GUARINO, J. B. CALL, V. T. OLIVERIO & J. B. BLOCK. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep. 54: 461-470.
5. MOERTEL, C. G., A. J. SCHUTT, R. J. REITEMEIER & R. G. HAHN. 1972. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56: 95-101.
6. GIOVANELLA, B. C., J. S. STEHLIN, M. E. WALL, M. C. WANI, A. W. NICHOLAS, L. F. LIU, R. SILBER & P. M. POTMESIL. 1989. DNA topoisomerase 1-targeted chemotherapy of human colon cancer xenografts. Science 246: 1046-1048.
7. PANTAZIS, P., H. R. HINZ, J. T. MENDOZA, A. S. KOZIELSKI, L. J. WILLIAMS, J. S. STEHLIN, JR. & B. C. GIOVANELLA. 1992. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 52: 3980-3987.
8. HOUGHTON, P. J., P. J. CHESHIRE, L. MYERS, C. F. STEWART, T. W. SYNOLD & J. A. HOUGHTON. 1992. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 31: 229-239.
9. FRIEDMAN, H. S., P. J. HOUGHTON, S. C. SCHOLD, S. KEIR & D. D. EIGNER. 1994. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 34: 171-174.
10. KUNIMOTO, T, K. NITTA, T. TANAKA, N. UEHARA, H. BABA, M. TAKEUCHI, T. YOKOKURA, S. SAWADA, T. MIYASAKA & M. MUTAI. 1987. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. 47: 5944-5947.
11. MATSUZAKI, T, T. YOKOKURA, M. MUTAI, & T. TSURUO. 1988. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 21: 308-312.
12. BISSERY, M. C., A. MATHIEU-BOUÉ & F. LAVELLE. 1991. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Am. Assoc. Cancer Res. 33: A2389.
13. BISSERY, M. C., A. MATHIEU-BOUÉ & F. LAVELLE. 1992. Experimental activity of CPT-11 in vitro and in vivo. Ann. Oncol. 3 (Suppl. 1): A093.
14. KAWATO, Y., T. FURUTA, M. AONUMA, M. YASUOKA, T. YOKOKURA, K. MATSUMOTO. 1991. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice Cancer Chemother. Pharmacol. 28: 192-198.
15. HOUGHTON, P. J., P. J. CHESHIRE, J. D. HALLMAN II, M. C. BISSERY, A. MATHIEU-BOUÉ & J. A. HOUGHTON. 1993. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyI-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin Cancer Res. 53: 2823-2829.
16. HOUGHTON, P. J., P. J. CHESHIRE, J. D. HALLMAN II, L. LUTZ, H. S. FRIEDMAN, M. K. DANKS & J. A. HOUGHTON. 1995. Efficacy of topoisomerase inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36: 393-403.
17. TSURUO, T., T. MATSUZAKI, M. MATSUSHITA, H. SAITO & T. YOKOKURA. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71-74.
18. TAGUCHI, T., A. WAKUI & K. HASEGAWA. 1990. Phase I clinical study of CPT-11. GanTo-Kagakuryoho 17: 115-120.
19. MASUDA, N., M. FUKUOKA, Y. KUSUNOKI, K. MATSUI, N. TAKIFUJI, S. KUDOH, S. NEGORO, M. NISHIOKA, K. NAKAGAWA & M. TAKADA. 1992. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10: 1225-1229.
20. FUJITA, A., H. TAKABATAKE, S. TAGAKI & K. SEKINE. 1995. Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho 22: 889-893.
21. OHNO, R., K. OKADA, T. MASAOKA, A. KURAMOTO, T. ARIMA, Y. YOSHIDA, H. ARIYOSHI, M. ICHIMARU, Y. SAKAI, M. OGURO, Y. ITO, Y. MORISHIMA, S. YOKOMAKU & K. OTA. 1990. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907-1912.
22. FUKUOKA, M., H. NIITANIM, A. SUZUKI, M. MOTOMIYA, K. HASEGAWA, Y. NISHIWAKI, T. KURIYAMA, Y. ARIYOSHI, S. NEGORO, N. MASUDA, S. NAKAJIMA & T. TAGUCHI. 1992. A phase 11 study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10: 16-20.
23. FUKUOKA, M., & N. MASUDA. 1994. Clinical studies of irinotecan and in combination with cisplatin. Cancer Chemother. Pharmacol. 34 (Suppl. 1): 105-111.
24. SHIMADA, Y., M. YOSHINO, A. WAKUI, I. NAKAO, K. FUTATSUKI, Y. SAKATA, M. KAMBE, T. TAGUCHI & N. OGAWA. 1993. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 11: 909-913.
25. NISHIMURA, G., T. SATOU, Y. YOSHIMITSU, Y. KUROSAKA, T. FUJIMURA, K. SUGIYAMA & Y. YONEMURA. 1995. Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer. Gan To Kagaku Ryoho 22: 93-97.
26. ROUGIER P., S. CULINE, R. BUGAT, P. BRUNET, J. Y. DOUILLARD & M. YCHOU. 1994. Multicentric phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC): preliminary results. Proc. Am. Soc. Clin. Oncol. 13: A585.
27. ROTHENBERG, M. L., J. R. ECKARDT, J, H. A. BURRIS, J. NELSON, J. G. KUHN & S. F. CHEN. 1994. Irinotecan (CPT-11) as second-line therapy for patients with 5-FU-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 13: A585.
28. PITOT, H. C., D. WENDER, M. J. O'CONNELL, H. S. WIEAND & J. A. MAILLIARD. 1994. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc. Am. Soc. Clin. Oncol. 13: A573.
29. BURRIS, H. A., M. L. ROTHENBERG, J. G. KUHN & D. D. VON HOFF. 1993. Clinical trials with the topoisomerase I inhibitors. Semin. Oncol. 19: 663-669.
30. MASUDA, N., M. FUKUOKA, S. KUDOH, Y. KUSUNOKI, K. MATSUI, N. TAKIFUJI, K. NAKAGAWA, M. TAMANOI & T. NITTA. 1993. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer Br. J. Cancer 68: 777-782.
31. MASUDA, N., M, FUKUOKA, S. KUDOH, Y. KUSUNOKI, K. MATSUI, K. NAKAGAWA, T. HIRASHIMA, M. TAMANOI, T. NITTA & T. YANA. 1994. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer J. Clin. Oncol. 12: 90-96.
32. SHINKAI, T., H. ARIOKA, H. KUNIKANE, K. EGUCHI, Y. SASAKI, T. TAMURA, Y. OHE, F. OSHITA, M. NISHIO & A. KARATO. 1994. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res. 54: 2636-2642.
33. SHIMADA, Y., Y. SASAKI, K. SUGANO, K. SHIRAO, H. KONDO, T. YOKOTA, D. SAITO, T. TAMURA, Y. OHE & T. SHINAKI. 1993. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc. Am. Assoc. Clin. Oncol. 12: A575.
34. NEGORO, S., M. FUKUOKA, N. MASUDA, Y. KUSUNOKI, K. MATSUI, S. KUDOH, N. TAKIFUJI, K. NAKAGAWA, T. HIRASHIMA & M. TAMANOI. 1993. Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer. Proc. Am. Assoc. Clin. Oncol. 12: A331.
35. MASUDA, N., M. FUKUOKA, S. KUDOH, K. MATSUI, Y. KUSUNOKI & M. TAKADA. 1994. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin Oncol. 12: 1833-1841.
36. HOUGHTON, P. J., J. A. HOUGHTON, L. MYERS, P. J. CHESHIRE, J. J. HOWBERT & G. B. GRINDEY. 1989. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol. 25: 84-88.
37. HOUGHTON, J. A. & D. M. TAYLOR. 1978. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br. J. Cancer 37: 213-219.
38. KAPLAN, E. L. & P. MEIER. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457-481.
39. PETO, R., M. C. PIKE, P. AMITAGE, N. E. BRESLOW, D. R. COX, S. Y. HOWARD, N. MANTEL, K. MCPHERSON, J. PETO & P. G. SMITH. 1977. Design and analysis of andomized clinical trials requiring prolonged observation of each patient. Part 2. Analysis and examples. Br. J. Cancer 35: 1-39.
40. WESTFALL, P. H. & S. S. YOUNG. 1989. P-value adjustments for multiple tests in multivariate binomial models. J. Am. Stat. Assoc. 84: 780-786. OSC, Chapter 21, page 19 (Ref. no. 40)40.
41. DEL-BINO, G. D, P. LASSOTA & Z. DARZYNKIEWICZ. 1991. The s-phase cytotoxicity of comptothecin. Exp. Cell. Res. 193: 27-35.
42. SASAKI, Y, Y. HAKUSUI, S. MIZUNO, M. MORITA, T. MIYA & K. EGUCHI. 1995. A pharmacokinetic and pharmacodynamic analysis od CPT-11 and its active metabolite, SN-38. Jpn. J. Cancer Res. 86: 101-110.
43. ABIGERGES, D. J. P. ARMAND, G. G. CHABOT, L. DA COSTA, E. FADEL, C. COTE, P. HERAIT & D. GANDIA. 1994. Irinotecan (CPT-11) high dose escalation with intensive high-dose loperamide to control diarrhea J. Natl. Cancer Inst. 86: 446.